Wednesday, October 14, 2026
Via News Knowledge File

Alphabet Inc.

organization80% conf.·synced Oct 14, 2026

Parent company of YouTube

60
sourced metrics
2892
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
402.62USD
Oct 13, 2026reference only
Market Cap
4326729400000USD
Oct 13, 2026reference only
Stock Return Ytd
12.3%
Oct 13, 2026reference only
Price 52 Week Low
245.45USD
Oct 13, 2026reference only
Stock Price
353.78USD
Oct 13, 2026reference only
Stockholders Equity
640480000000.0USD
Jun 30, 2026reference only
Total Liabilities
281503000000.0USD
Jun 30, 2026reference only
Rd Expense
18219000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
45943000000.0USD
Jun 30, 2026reference only
Operating Income
40770000000.0USD
Jun 30, 2026reference only
Eps
9.11USD_per_share
Jun 30, 2026reference only
Revenue
119796000000.0USD
Jun 30, 2026reference only
Total Assets
921983000000.0USD
Jun 30, 2026reference only
Shares Outstanding
12230000000.0shares
Jun 30, 2026reference only
Net Income
112193000000.0USD
Jun 30, 2026reference only
Cash
55911000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
45790000000.0USD
Mar 31, 2026reference only
Capex
35674000000.0USD
Mar 31, 2026reference only

Stated objectives

Potentially ~44% growth in Google Cloud in early 2025

source
target: 44% stated

Higher capital deployment for AI and cloud infrastructure

source
target: ~$29B stated

Achieve $4 trillion market cap

source
target: 4 trillion USD stated

Ramp up AI investment to as high as $185 billion

source
target: 185 billion USD by 2026-01-01 00:00:00stated

Ramp up AI investment to as high as $185 billion

source
target: 185 billion USD stated

Sustain low-mid-teens% Search revenue growth

source
target: 10-15% by 2026-01-01 00:00:00stated

Spend between $175-185 billion on AI infrastructure in 2026

source
target: 175-185 billion USD by 2026-12-31 00:00:00stated

Capital expenditure range for AI infrastructure in 2026

source
target: 175-185 billion USD by 2026-12-31 00:00:00stated

AI investment buildout and infrastructure expansion

source
target: 180-185 billion USD by 2026-12-31 00:00:00stated

Capital expenditures between $175 billion and $185 billion for AI infrastructure

source
target: 175-185 billion USD by 2026-12-31 00:00:00stated

Relationship graph · 2892 connections

Competes with
640
Developed by
607
subsidiary of
294
Supplies to
249
Covered by
181
Invested in
156
Customer of
118
Owns
103

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com